Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer | American Society of Clinical Oncology Educational Book
ASCO GU 2022: Association between PROs and Changes in PSA in Patients with Advanced Prostate Cancer Treated with Apalutamide in the SPARTAN and TITAN Studies
ASCO 2019: Efficacy of Apalutamide plus Ongoing Androgen Deprivation Therapy in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Baseline Comorbidities
ESMO 2019: Apalutamide and Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Updated Results From the Phase 3 SPARTAN Study
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Managing Nonmetastatic Castration-resistant Prostate Cancer - European Urology
Case 1: SPARTAN Trial for Apalutamide in nmCRPC
Updates and Insights on the Medical Science of Prostate Cancer (Transcript)
Pivotal Trials Efficacy Data | For HCPs | REYVOW® (lasmiditan)
Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
Pushing Ahead With New Treatments for Nonmetastatic Castration-Resistant Prostate Cancer
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
ASCO 2020: Molecular Determinants of PSA Kinetics and Clinical Response to Apalutamide in Patients with nmCRPC in SPARTAN
ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
SPARTAN: quality of life related to the use of apalutamide in patients with castration-resistant non-metastatic prostate cancer - Onco Americas
Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment | American Society of Clinical Oncology Educational Book
Final Analysis of SPARTAN Study
Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Treatment and trials in non-metastatic castration-resistant prostate cancer | Nature Reviews Urology
Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
